Business Wire

Panasonic Presents the Latest Highlights in Automated and Connected Vehicle Technologies and ITS Big Data Solutions

Del

Panasonic is exhibiting the latest highlights in automated and connected vehicle technologies and Intelligent Transport Systems (ITS) big data solutions at ITS World Congress 2015, Bordeaux, where over 300 car manufacturers and suppliers are on full display. At the Panasonic Booth, the corporation is putting on full display its repertoire in two key areas: automated and connected vehicle technologies and ITS big data solutions.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151010005001/en/

Panasonic booth at ITS 2015 (Photo: Business Wire)

Panasonic booth at ITS 2015 (Photo: Business Wire)

[Flash Video] Panasonic’s Automated & Connected Technologies @ #ITSWC15
https://www.youtube.com/watch?t=22&v=ReexhHCdAMs
http://news.panasonic.com/global/topics/2015/44285.html

Offering automotive and device solutions for pedestrians and cars, infrastructure solutions for homes, roads and more, Panasonic is one of the few manufacturers capable of providing total solutions. Based on the concept of bringing together comfort, safety and the environment, Panasonic is using these strengths as part of the evolution of ITS.

Trends in the Automotive Industry

ERTICOーITS Europe, the organizer of ITS World Congress 2015, is highlighting industry aims to create safer, smarter and cleaner mobility. This vision aims also to result in people becoming fully informed, reducing the impact of vehicles on the environment and minimizing the amount of traffic accidents.
In the report 'Analysis of the Advanced Driver Assistance Systems (ADAS) Market in Europe', Frost & Sullivan Research Analyst Cathy Brown points out that vehicle safety and driver comfort are currently garnering immense interest within the automotive industry. "Driven by legislation and cost effective vehicles, the ADAS market in Europe is entering a new phase of applications integrating both safety and comfort." as Brown notes, this have become focal points of assessment, and companies are using all means to meet the modern demands while also considering future technology.

Panasonic's Business Strategy for the future of Automotive industry
According to Masahisa Shibata, President of Panasonic Automotive and Industrial Systems Europe, Panasonic's global strategy focuses on three key business areas:

  1. Infotainment and e-cockpit solutions to provide more comfort and entertainment to the driver as well as co-passengers.
  2. Advanced driving assistance systems for maximum safety.
  3. Environmental solutions with more efficient electronics and best-in-class battery technology for EVs (Electric Vehicles).

Regarding Panasonic's business strategy for Europe, Yoshitaka Teraoka, Vice President of Panasonic Automotive and Industrial Systems Europe GmbH says, "What makes us unique is that we can cross-pollinate between various consumer and B2B areas by utilizing our comprehensive portfolio. Developing next generation solutions for these three areas and working closely with advanced companies, we aim to become a leading partner of our customers in Europe."

Panasonic's technology development for ADAS

Panasonic is developing ADAS technology by utilizing its strengths in cameras, sensors and image-processing technology. The Panasonic millimeter-wave radar system detects the position of other vehicles and pedestrians in less than 0.1 seconds and informs the driver through road-to-vehicle communication.

Panasonic's 79GHz Infrastructure Radar for cooperative intersection safety is precise and covers a wide scope. It features high resolution for differentiating between pedestrians and other vehicles, a wide field of view for scanning, and high-level accuracy for detecting multiple targets with its robustness at night and under poor weather conditions (snow, fog, etc.).
The V2X Communication for Driving Support System is a key technology for new driving support systems. Covering vehicle-to-vehicle (V2V), vehicle-to-infrastructure (V2I) and vehicle-to-pedestrian (V2P), the V2X Communication for Driving Support System helps prevent traffic accidents by alerting the driver of impending hazardous situations.
Recognizing the surrounding environment to provide support for the driver, the High-Performance Pedestrian Detection based on Deep Learning estimates pedestrian behaviors − providing a detection algorithm for on-vehicle cameras to predict accident risks.

Developing ADAS business in Europe −Panasonic's business alliance with Ficosa
The capital and business alliance with Ficosa will allow Panasonic to launch its electronic mirror business while also expanding its ADAS portfolio. Based in Spain, Ficosa is a tier 1 global provider for the automotive industry. Through their collaboration in electronic mirror systems, Ficosa and Panasonic are accelerating the continued evolution of automobile comfort and safety - both areas being at the core of next-generation cockpit systems.

"This partnership will not only bring complementary know-how and technologies but also regional synergies, says Javier Pujol, CEO of Ficosa International S.A. "Our customers will truly benefit from the close collaboration of both of our companies − for instance, when it comes to next generation cockpit systems."

At the automated and connected vehicle technologies corner, Panasonic is presenting its Intelligent Rearview Monitor System, which is comprised of a camera and mirror display. When operating in Mirror Mode, the system makes images available to the driver as per Class I mirrors; when working in camera monitor system mode, it displays images coming from the rear camera, and a side-view camera makes visible what would otherwise be blindspots.

Keeping a close eye on electric vehicle hackers
Due to increased communications connectivity, vehicles have become more vulnerable to being attacked by hackers. Panasonic is leading the development of automotive security technologies to protect vehicle networks − its Security Electronic Control Unit (ECU) for Disabling Malicious Controller Area Network (CAN) Messages detecting unusual behavior such as unexpected acceleration and disables malicious commands.

Big data utilization in the field of ITS
In the corner of ITS Big Data Solutions, Panasonic is presenting the possibilities of ITS utilization to provide solutions for a wide range of issues. For B2B, Panasonic's Logistics Probe Solutions enables professionals such as logistic managers to better monitor vehicles and road managers to more easily acquire information about the status of roads by utilizing a Dedicated Short Range Communication (DSRC) On-board Unit with GPS.

For B2C, Panasonic provides convenient and enjoyable travel experiences with greater safety and sense of security. Called the Wonder Trip System, it supports travelers in all destinations through personal authentication technology. Furthermore, Panasonic provides communication and content customization through transport information integration in smartphones and wearable devices.

As one of the few manufacturers capable of providing total solutions, Panasonic hopes that these solutions will contribute to a safer, greener and more comfortable world. In short, "A Better Life, A Better World".

Panasonic Booth at ITS World Congress
Period: 5th-9th October 2015
Location: Rue Jean Samazeuilh BP 55 33030 Bordeaux Cedex France

Related Links

Panasonic Automotive & Industrial Systems Europe
Panasonic's Business Solutions
Automotive & Industrial Systems Company, Panasonic Corporation
ITS World Congress Official Site
[Photo Album] Panasonic at #ITSWC15

Contact information

Panasonic Corporation
Global Communications Department
Media Promotion Office
+81-3-3574-5729
presscontact@ml.jp.panasonic.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom